Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Bioassay of plasma specimens from liver transplant patients on FK 506 immunosuppression.

Literature DB >> 1689902

Bioassay of plasma specimens from liver transplant patients on FK 506 immunosuppression.

A Zeevi¹, G Eiras, G Burckart, A Jain, A Kragack, R Venkataramanan, S Todo, J Fung, T E Starzl, R J Duquesnoy.

Abstract

Entities: Chemical Species

Mesh：

Substances：

Year: 1990 PMID： 1689902 PMCID： PMC2903871

Source DB: PubMed Journal: Transplant Proc ISSN： 0041-1345 Impact factor: 1.066

× No keyword cloud information.

13 in total

1. Assay of FK 506 in plasma.

Authors: E M Cadoff; R Venkataramanan; A Krajack; A S Jain; J J Fung; S Todo; T E Starzl
Journal: Transplant Proc Date: 1990-02 Impact factor: 1.066

2. Effect of a new immunosuppressive agent, FK 506, on heterotopic cardiac allotransplantation in the rat.

Authors: T Ochiai; K Nakajima; M Nagata; T Suzuki; T Asano; T Uematsu; T Goto; S Hori; T Kenmochi; T Nakagoori
Journal: Transplant Proc Date: 1987-02 Impact factor: 1.066

3. Renal transplantation in baboons under FK 506.

Authors: S Todo; A Demetris; Y Ueda; O Imventarza; E Cadoff; A Zeevi; T E Starzl
Journal: Surgery Date: 1989-08 Impact factor: 3.982

4. Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A.

Authors: A Zeevi; R Duquesnoy; G Eiras; H Rabinowich; S Todo; L Makowka; T E Starzl
Journal: Transplant Proc Date: 1987-10 Impact factor: 1.066

5. A highly sensitive method to assay FK-506 levels in plasma.

Authors: K Tamura; M Kobayashi; K Hashimoto; K Kojima; K Nagase; K Iwasaki; T Kaizu; H Tanaka; M Niwa
Journal: Transplant Proc Date: 1987-10 Impact factor: 1.066

6. Immunopharmacodynamic profiles in children with renal allografts receiving cyclosporine therapy.

Authors: L Reisman; K V Lieberman; G P Martinelli; K E Bowles; H Schanzer; L Burrows
Journal: Am J Kidney Dis Date: 1988-08 Impact factor: 8.860

Review 7. Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters.

Authors: B D Kahan
Journal: Transplantation Date: 1985-11 Impact factor: 4.939

8. Cyclosporine trough concentration monitoring in liver transplant patients.

Authors: G J Burckart; R J Ptachcinski; R Venkataramanan; S Iwatsuki; C Esquivel; D H Van Thiel; T E Starzl
Journal: Transplant Proc Date: 1986-12 Impact factor: 1.066

9. Specificity of alloactivated human T lymphocyte clones in secondary proliferation, cell-mediated lympholysis and interleukin-2 release.

Authors: A Zeevi; R J Duquesnoy
Journal: J Immunogenet Date: 1985-02

10. Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction.

Authors: S Todo; Y Ueda; J A Demetris; O Imventarza; M Nalesnik; R Venkataramanan; L Makowka; T E Starzl
Journal: Surgery Date: 1988-08 Impact factor: 3.982

10 in total

Bioassay of plasma specimens from liver transplant patients on FK 506 immunosuppression.

1. Assay of FK 506 in plasma.

2. Effect of a new immunosuppressive agent, FK 506, on heterotopic cardiac allotransplantation in the rat.

3. Renal transplantation in baboons under FK 506.

4. Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A.

5. A highly sensitive method to assay FK-506 levels in plasma.

6. Immunopharmacodynamic profiles in children with renal allografts receiving cyclosporine therapy.

Review 7. Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters.

8. Cyclosporine trough concentration monitoring in liver transplant patients.

9. Specificity of alloactivated human T lymphocyte clones in secondary proliferation, cell-mediated lympholysis and interleukin-2 release.

10. Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction.

1. Low-dose of FK 506 and associated blood levels in allotransplantation of rat liver, heart, and skin.

Review 2. In vitro assessment of FK 506 immunosuppressive activity in transplant patients.

3. The effect of FK 506 on peripheral blood T-lymphocyte subsets in orthotopic liver transplant patients.

4. Distribution of FK 506 in plasma lipoproteins in transplant patients.

Review 5. The use of therapeutic drug monitoring to optimise immunosuppressive therapy.

Review 6. Clinically significant drug interactions with new immunosuppressive agents.

7. Tacrolimus analysis: a comparison of different methods and matrices.

Review 8. Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation.

Review 9. Clinical pharmacokinetics of tacrolimus.

Review 10. Mechanisms of clinically relevant drug interactions associated with tacrolimus.